Empresa Foamix Pharmaceuticals Ltd. Nasdaq
Acciones
IL0011334385
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01/03/20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/03/20 |
Mutya Harsch
LAW | General Counsel | 50 | 01/03/20 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10/09/20 |
Steven Basta
BRD | Director/Board Member | 59 | 01/01/15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01/03/20 |
Director/Board Member | 62 | 01/03/19 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 01/03/20 |
Director/Board Member | - | 01/01 | |
Sharon Barbari
BRD | Director/Board Member | 70 | 01/03/20 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 14 528 247 | 13 300 238 ( 91,55 %) | 0 | 91,55 % |
Información de la empresa
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.com![Dirección Foamix Pharmaceuticals Ltd.](https://cdn.zonebourse.com/static/address/17927322.png)
Sector
Varia. 1 de ene. | Capi. | |
---|---|---|
+20,39 % | 127 mil M | |
+24,41 % | 117 mil M | |
+25,44 % | 27,67 mil M | |
-18,09 % | 20,33 mil M | |
-15,17 % | 16,79 mil M | |
-14,73 % | 15,63 mil M | |
+12,65 % | 14,84 mil M | |
-47,10 % | 14,65 mil M | |
+56,17 % | 14,43 mil M |